Form 4: GeneDx Holdings CEO Katherine Stueland Reports Stock Transactions

Katherine Stueland, CEO of GeneDx Holdings Corp., reports acquisition and disposal of Class A Common Stock related to RSU vesting and tax obligations.

Summary

• Katherine Stueland, the CEO of GeneDx Holdings Corp., filed a Form 4 detailing changes in her beneficial ownership of the company's stock.
• On September 16, 2024, she acquired 18,750 shares of Class A Common Stock upon the vesting of restricted stock units (RSUs) at a price of $0.
• Simultaneously, she sold 10,501 shares of Class A Common Stock at $37.59 per share to cover tax withholding obligations associated with the RSU vesting.
• Following these transactions, Stueland directly owns 103,706 shares of Class A Common Stock and 187,500 derivative securities in the form of RSUs.
• The RSUs vest in quarterly installments over a 4-year period starting March 16, 2023.

Sentiment

Score: 6

Explanation: The sentiment is neutral as the filing reflects routine transactions related to executive compensation. There are no indications of unusual or concerning activity.

Positives

• The vesting of RSUs indicates a continued alignment of the CEO's interests with the company's performance.
• The 'sell to cover' transaction is a common practice for managing tax obligations related to equity compensation.

Industry Context

Form 4 filings are standard practice and provide transparency into the trading activities of company insiders, allowing investors to monitor executive compensation and potential alignment with shareholder interests.

Stakeholder Impact

• The transactions provide transparency to shareholders regarding executive compensation and stock ownership.
• The 'sell to cover' transaction has a minor impact on the stock's trading volume.

Key Dates